In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

or lab-made protein. It has generated promising results in clinical trials for treatment of kidney disorders that involve the immune system. Dr. Priya Singhal, Biogen’s head of development ...

Biogen retains an interest in treating Parkinson’s by targeting LRRK2, with BIIB122, an inhibitor of the protein, remaining in the biotech’s phase 2 pipeline. Finally, Biogen brought an end to ...

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche ... with Greek mythology from the name of the protein that is targeted by the RNAi drug ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

Biogen has revealed encouraging phase 2 results ... is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. It is thought that CD38-expressing ...

Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner ... deposits of a protein called amyloid ...

Biogen and Eisai’s Alzheimer’s disease (AD ... Leqembi works by binding to and reducing clumps of amyloid beta protein that form plaques in the brain. However, AD progression does not stop after ...